Loading clinical trials...
Loading clinical trials...
Interest of Virtual Reality Distraction in the Management of Patients Benefiting From Oocyte Retrieval
This study compares hypnosis via virtual reality to sedation with commonly used intravenous anesthetic agents (propofol and remifentanil) during oocyte retrieval. The main objective of this prospective randomized controlled study will be a reduction of 50 percent of the doses of remifentanil and propofol administered during oocyte retrieval while maintaining satisfaction with the quality of care.
Transvaginal ultrasound-guided oocyte retrieval is a fundamental step in the treatment of in vitro fertilization (IVF). To date, no anesthetic technique has demonstrated superiority in terms of efficacy, tolerance or analgesia. Virtual Reality Distraction has been studied for its clinical applications. Patients will be included during the consultation with either the gynecologist or the anesthetist who will explain the protocol to the patient and give her consent to sign. After obtaining their informed consent, the patient will be randomized into two groups based on a computer-generated randomization list (QuickCalcs program; GraphPad Software Inc) either into the experimental or in the control group. In the experimental group, patients will benefit from a 20-minute virtual reality. Patients will watch a forest walk in virtual reality while listening to narrations designed to induce relaxation and meditation. If the oocyte retrieval was not completed within 20 minutes, the patient will watch the virtual reality program again. The target-controlled infusion of remifentanil and propofol will be connected to the patient, and only titrated to patient's comfort. In the control group, patients will immediately benefit from an infusion of remifentanil and propofol titrated in a well-protocolized manner according to the patient's comfort.
Age
18 - 45 years
Sex
FEMALE
Healthy Volunteers
No
Erasme University Hospital
Brussels, Belgium
Start Date
February 1, 2022
Primary Completion Date
April 11, 2022
Completion Date
April 11, 2022
Last Updated
April 25, 2022
48
ACTUAL participants
Virtual reality distraction
DEVICE
Propofol-remifentanil sedation
DRUG
Lead Sponsor
Erasme University Hospital
NCT07222007
NCT07259291
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions